Matinas BioPharma Holdings (MTNB) Equity Ratio (2013 - 2026)

Matinas BioPharma Holdings (MTNB) has 14 years of Equity Ratio data on file, last reported at 0.51 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.51, down 1.25% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.51 (down 1.25% YoY), and the FY2025 annual result was 0.67, up 11.6% from the prior year.
• Equity Ratio slipped to 0.51 in Q1 2026 per MTNB's latest filing, from 0.67 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.85 in Q1 2022 and troughed at 0.51 in Q1 2026.
• A 5-year average of 0.73 and a median of 0.77 in 2024 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 11.6% in 2025 and fell as far as 29.82% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.82 in 2022, then dropped by 6.21% to 0.77 in 2023, then decreased by 21.68% to 0.6 in 2024, then grew by 11.6% to 0.67 in 2025, then dropped by 23.22% to 0.51 in 2026.
• Business Quant data shows MTNB's Equity Ratio at 0.51 in Q1 2026, 0.67 in Q4 2025, and 0.67 in Q3 2025.